Cargando…

Poly(3-Hydroxybutyrate)-Based Nanoparticles for Sorafenib and Doxorubicin Anticancer Drug Delivery

Dual drug-loaded nanotherapeutics can play an important role against the drug resistance and side effects of the single drugs. Doxorubicin and sorafenib were efficiently co-encapsulated by tailor-made poly([R,S]-3-hydroxybutyrate) (PHB) using an emulsion–solvent evaporation method. Subsequent poly(e...

Descripción completa

Detalles Bibliográficos
Autores principales: Babos, György, Rydz, Joanna, Kawalec, Michal, Klim, Magdalena, Fodor-Kardos, Andrea, Trif, László, Feczkó, Tivadar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7582498/
https://www.ncbi.nlm.nih.gov/pubmed/33022990
http://dx.doi.org/10.3390/ijms21197312
_version_ 1783599205632180224
author Babos, György
Rydz, Joanna
Kawalec, Michal
Klim, Magdalena
Fodor-Kardos, Andrea
Trif, László
Feczkó, Tivadar
author_facet Babos, György
Rydz, Joanna
Kawalec, Michal
Klim, Magdalena
Fodor-Kardos, Andrea
Trif, László
Feczkó, Tivadar
author_sort Babos, György
collection PubMed
description Dual drug-loaded nanotherapeutics can play an important role against the drug resistance and side effects of the single drugs. Doxorubicin and sorafenib were efficiently co-encapsulated by tailor-made poly([R,S]-3-hydroxybutyrate) (PHB) using an emulsion–solvent evaporation method. Subsequent poly(ethylene glycol) (PEG) conjugation onto nanoparticles was applied to make the nanocarriers stealth and to improve their drug release characteristics. Monodisperse PHB–sorafenib–doxorubicin nanoparticles had an average size of 199.3 nm, which was increased to 250.5 nm after PEGylation. The nanoparticle yield and encapsulation efficiencies of drugs decreased slightly in consequence of PEG conjugation. The drug release of the doxorubicin was beneficial, since it was liberated faster in a tumor-specific acidic environment than in blood plasma. The PEG attachment decelerated the release of both the doxorubicin and the sorafenib, however, the release of the latter drug remained still significantly faster with increased initial burst compared to doxorubicin. Nevertheless, the PEG–PHB copolymer showed more beneficial drug release kinetics in vitro in comparison with our recently developed PEGylated poly(lactic-co-glycolic acid) nanoparticles loaded with the same drugs.
format Online
Article
Text
id pubmed-7582498
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-75824982020-10-29 Poly(3-Hydroxybutyrate)-Based Nanoparticles for Sorafenib and Doxorubicin Anticancer Drug Delivery Babos, György Rydz, Joanna Kawalec, Michal Klim, Magdalena Fodor-Kardos, Andrea Trif, László Feczkó, Tivadar Int J Mol Sci Article Dual drug-loaded nanotherapeutics can play an important role against the drug resistance and side effects of the single drugs. Doxorubicin and sorafenib were efficiently co-encapsulated by tailor-made poly([R,S]-3-hydroxybutyrate) (PHB) using an emulsion–solvent evaporation method. Subsequent poly(ethylene glycol) (PEG) conjugation onto nanoparticles was applied to make the nanocarriers stealth and to improve their drug release characteristics. Monodisperse PHB–sorafenib–doxorubicin nanoparticles had an average size of 199.3 nm, which was increased to 250.5 nm after PEGylation. The nanoparticle yield and encapsulation efficiencies of drugs decreased slightly in consequence of PEG conjugation. The drug release of the doxorubicin was beneficial, since it was liberated faster in a tumor-specific acidic environment than in blood plasma. The PEG attachment decelerated the release of both the doxorubicin and the sorafenib, however, the release of the latter drug remained still significantly faster with increased initial burst compared to doxorubicin. Nevertheless, the PEG–PHB copolymer showed more beneficial drug release kinetics in vitro in comparison with our recently developed PEGylated poly(lactic-co-glycolic acid) nanoparticles loaded with the same drugs. MDPI 2020-10-03 /pmc/articles/PMC7582498/ /pubmed/33022990 http://dx.doi.org/10.3390/ijms21197312 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Babos, György
Rydz, Joanna
Kawalec, Michal
Klim, Magdalena
Fodor-Kardos, Andrea
Trif, László
Feczkó, Tivadar
Poly(3-Hydroxybutyrate)-Based Nanoparticles for Sorafenib and Doxorubicin Anticancer Drug Delivery
title Poly(3-Hydroxybutyrate)-Based Nanoparticles for Sorafenib and Doxorubicin Anticancer Drug Delivery
title_full Poly(3-Hydroxybutyrate)-Based Nanoparticles for Sorafenib and Doxorubicin Anticancer Drug Delivery
title_fullStr Poly(3-Hydroxybutyrate)-Based Nanoparticles for Sorafenib and Doxorubicin Anticancer Drug Delivery
title_full_unstemmed Poly(3-Hydroxybutyrate)-Based Nanoparticles for Sorafenib and Doxorubicin Anticancer Drug Delivery
title_short Poly(3-Hydroxybutyrate)-Based Nanoparticles for Sorafenib and Doxorubicin Anticancer Drug Delivery
title_sort poly(3-hydroxybutyrate)-based nanoparticles for sorafenib and doxorubicin anticancer drug delivery
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7582498/
https://www.ncbi.nlm.nih.gov/pubmed/33022990
http://dx.doi.org/10.3390/ijms21197312
work_keys_str_mv AT babosgyorgy poly3hydroxybutyratebasednanoparticlesforsorafenibanddoxorubicinanticancerdrugdelivery
AT rydzjoanna poly3hydroxybutyratebasednanoparticlesforsorafenibanddoxorubicinanticancerdrugdelivery
AT kawalecmichal poly3hydroxybutyratebasednanoparticlesforsorafenibanddoxorubicinanticancerdrugdelivery
AT klimmagdalena poly3hydroxybutyratebasednanoparticlesforsorafenibanddoxorubicinanticancerdrugdelivery
AT fodorkardosandrea poly3hydroxybutyratebasednanoparticlesforsorafenibanddoxorubicinanticancerdrugdelivery
AT triflaszlo poly3hydroxybutyratebasednanoparticlesforsorafenibanddoxorubicinanticancerdrugdelivery
AT feczkotivadar poly3hydroxybutyratebasednanoparticlesforsorafenibanddoxorubicinanticancerdrugdelivery